Companies obviously benefit by expanding the indications for their drugs. What drives this process isn't always obvious, however.

As it sometimes turns out, testing of new indications may be driven as often by the need of clinicians for new treatments as it is by a corporate desire for more sales. In the case of supplementary indications for angiotension-II receptor antagonists (AIIRAs), originally marketed to treat hypertension, it appears that pharma companies followed the lead of physicians and basic research scientists who were intent on treating patients with chronic nephropathy.